Ruthenium(II) Arene Compounds as Versatile Anticancer Agents
Ruthenium-based compounds are an attractive alternative to clinically used platinum drugs due to several features including a wide range of accessible oxidation states, varied synthetic chemistry and typically lower general toxicities. One series of ruthenium(II)-arene-pta, RAPTA (pta = 1,3,5-triaza-7-phosphatricyclo[126.96.36.199] decane) compounds has been found to show particularly high selectivity towards cancer cells in both in vitro and in vivo studies.
Keywords: Anticancer ; Bioorganometallic ; Chemotherapy ; Ruthenium ; Antitumor Drugs ; Pta Complexes ; Organometallic Ruthenium(Ii) ; In-Vitro ; Nami-A ; Binding ; Hydrolysis ; Targets ; Cancer ; Dna
Record created on 2010-11-30, modified on 2016-08-09